Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspective
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Vigilância Sanitária em Debate |
Texto Completo: | https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1710 |
Resumo: | Introduction: The risk of drug shortages due to the COVID-19 pandemic required from national health authorities to take quick actions in order to avoid it and, at the same time, preserve the maintenance of a minimum standard of quality, safety and efficacy of medicines, as National Health Regulatory Agency (Anvisa) did by publishing RDC nº 392/2020. Objective: To carry out a comparative analysis between the exceptionalities listed in article 7 of RDC nº 392/2020 with the requirements of good manufacturing practices (GMP) exceptionally relaxed by foreign health authorities due to COVID-19, showing, whenever necessary, the impact of these requirements on the quality of medicines made available to the population. Method: A selective search was made for documents related to the temporary flexibility of GMP requirements for medicines and pharmaceutical ingredients during the COVID-19 pandemic at the electronic addresses on the internet of some health authorities. Such requirements were critically compared with those listed in article 7 of RDC nº 392/2020. Results: Exceptionalities were presented in a Table, detailing the topics and subtopics found in the analyzed documents of MHRA, EMA and Anvisa. More similarities were verified than differences between the flexible requirements, perhaps because RDC nº 392/2020 was prepared considering the documents referenced here from MHRA and EMA. Conclusions: Despite the mistakes pointed out and the criticisms made to RDC nº 392/2020, the merit of Anvisa cannot be diminished, as it was shown that regardless of the territory in which the regulatory agencies are located, there is considerable convergence among Brazilian expectations and those of the other health authorities consulted. |
id |
FIOCRUZ-9_83aca088ea506b398ead6eed58b0b52b |
---|---|
oai_identifier_str |
oai:ojs.visaemdebate.incqs.fiocruz.br:article/1710 |
network_acronym_str |
FIOCRUZ-9 |
network_name_str |
Vigilância Sanitária em Debate |
repository_id_str |
|
spelling |
Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspectiveA flexibilização de requisitos brasileiros de Boas Práticas de Fabricação durante a pandemia da COVID-19 sob uma perspectiva comparadaCOVID-19AnvisaGood Manufacturing PracticesMedicinesFlexibilizationCOVID-19AnvisaBoas Práticas de FabricaçãoMedicamentosFlexibilizaçãoIntroduction: The risk of drug shortages due to the COVID-19 pandemic required from national health authorities to take quick actions in order to avoid it and, at the same time, preserve the maintenance of a minimum standard of quality, safety and efficacy of medicines, as National Health Regulatory Agency (Anvisa) did by publishing RDC nº 392/2020. Objective: To carry out a comparative analysis between the exceptionalities listed in article 7 of RDC nº 392/2020 with the requirements of good manufacturing practices (GMP) exceptionally relaxed by foreign health authorities due to COVID-19, showing, whenever necessary, the impact of these requirements on the quality of medicines made available to the population. Method: A selective search was made for documents related to the temporary flexibility of GMP requirements for medicines and pharmaceutical ingredients during the COVID-19 pandemic at the electronic addresses on the internet of some health authorities. Such requirements were critically compared with those listed in article 7 of RDC nº 392/2020. Results: Exceptionalities were presented in a Table, detailing the topics and subtopics found in the analyzed documents of MHRA, EMA and Anvisa. More similarities were verified than differences between the flexible requirements, perhaps because RDC nº 392/2020 was prepared considering the documents referenced here from MHRA and EMA. Conclusions: Despite the mistakes pointed out and the criticisms made to RDC nº 392/2020, the merit of Anvisa cannot be diminished, as it was shown that regardless of the territory in which the regulatory agencies are located, there is considerable convergence among Brazilian expectations and those of the other health authorities consulted.Introdução: O risco de desabastecimento de medicamentos em razão da pandemia da COVID-19 exigiu das autoridades sanitárias de alguns países medidas rápidas para tentar evitá-lo e, ao mesmo tempo, preservar a manutenção de um padrão mínimo de qualidade, segurança e eficácia dos medicamentos, como fez a Agência Nacional de Vigilância Sanitária (Anvisa), ao publicar a Resolução da Diretoria Colegiada (RDC) nº 392, de 26 de maio de 2020. Objetivo: Realizar análise comparativa entre as excepcionalidades elencadas no artigo 7º da RDC nº 392/2020 com os requisitos de boas práticas de fabricação (BPF) excepcionalmente flexibilizados por autoridades sanitárias estrangeiras em razão da COVID-19, evidenciando, sempre que necessário, o impacto desses requisitos para a qualidade dos medicamentos disponibilizados à população. Método: Foi feita a busca seletiva por documentos relacionados à flexibilização transitória de requisitos de BPF de medicamentos e de insumos farmacêuticos durante a pandemia da COVID-19 nos endereços eletrônicos existentes na internet de algumas autoridades sanitárias. Tais requisitos foram criticamente comparados com aqueles elencados no artigo 7º da RDC nº 392/2020. Resultados: As excepcionalidades foram discriminadas em tópicos e subtópicos encontrados nos documentos analisados da MHRA, EMA e Anvisa. Foram verificadas mais semelhanças do que diferenças entre os requisitos flexibilizados, talvez porque a RDC nº 392/2020 tenha sido elaborada considerando os documentos aqui referenciados da MHRA e EMA. Conclusões: Em que pese os equívocos apontados e as críticas realizadas à RDC nº 392/2020, o mérito da atuação da Anvisa em nada pode ser diminuído, pois foi evidenciado que, independentemente do território em que estejam localizadas as agências reguladoras, há considerável convergência das expectativas brasileiras com as das demais autoridades sanitárias consultadas.Instituto Nacional de Controle de Qualidade em Saúde2020-07-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1710Health Surveillance under Debate: Society, Science & Technology ; Vol. 8 No. 3 (2020): August; 44-51Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 8 Núm. 3 (2020): Agosto; 44-51Vigil Sanit Debate, Rio de Janeiro; v. 8 n. 3 (2020): Agosto; 44-512317-269Xreponame:Vigilância Sanitária em Debateinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporenghttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1710/1206https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1710/1277Copyright (c) 2020 Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debatehttps://creativecommons.org/licenses/by/3.0/deed.pt_BRinfo:eu-repo/semantics/openAccessCassano, Adriano OlianAreda, Camila Alves2023-06-27T15:12:36Zoai:ojs.visaemdebate.incqs.fiocruz.br:article/1710Revistahttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebatePUBhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/oaiincqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br2317-269X2317-269Xopendoar:2023-06-27T15:12:36Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.none.fl_str_mv |
Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspective A flexibilização de requisitos brasileiros de Boas Práticas de Fabricação durante a pandemia da COVID-19 sob uma perspectiva comparada |
title |
Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspective |
spellingShingle |
Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspective Cassano, Adriano Olian COVID-19 Anvisa Good Manufacturing Practices Medicines Flexibilization COVID-19 Anvisa Boas Práticas de Fabricação Medicamentos Flexibilização |
title_short |
Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspective |
title_full |
Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspective |
title_fullStr |
Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspective |
title_full_unstemmed |
Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspective |
title_sort |
Flexibilization of Brazilian Good Manufacturing Practices requirements during COVID-19 outbreak in a comparative perspective |
author |
Cassano, Adriano Olian |
author_facet |
Cassano, Adriano Olian Areda, Camila Alves |
author_role |
author |
author2 |
Areda, Camila Alves |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Cassano, Adriano Olian Areda, Camila Alves |
dc.subject.por.fl_str_mv |
COVID-19 Anvisa Good Manufacturing Practices Medicines Flexibilization COVID-19 Anvisa Boas Práticas de Fabricação Medicamentos Flexibilização |
topic |
COVID-19 Anvisa Good Manufacturing Practices Medicines Flexibilization COVID-19 Anvisa Boas Práticas de Fabricação Medicamentos Flexibilização |
description |
Introduction: The risk of drug shortages due to the COVID-19 pandemic required from national health authorities to take quick actions in order to avoid it and, at the same time, preserve the maintenance of a minimum standard of quality, safety and efficacy of medicines, as National Health Regulatory Agency (Anvisa) did by publishing RDC nº 392/2020. Objective: To carry out a comparative analysis between the exceptionalities listed in article 7 of RDC nº 392/2020 with the requirements of good manufacturing practices (GMP) exceptionally relaxed by foreign health authorities due to COVID-19, showing, whenever necessary, the impact of these requirements on the quality of medicines made available to the population. Method: A selective search was made for documents related to the temporary flexibility of GMP requirements for medicines and pharmaceutical ingredients during the COVID-19 pandemic at the electronic addresses on the internet of some health authorities. Such requirements were critically compared with those listed in article 7 of RDC nº 392/2020. Results: Exceptionalities were presented in a Table, detailing the topics and subtopics found in the analyzed documents of MHRA, EMA and Anvisa. More similarities were verified than differences between the flexible requirements, perhaps because RDC nº 392/2020 was prepared considering the documents referenced here from MHRA and EMA. Conclusions: Despite the mistakes pointed out and the criticisms made to RDC nº 392/2020, the merit of Anvisa cannot be diminished, as it was shown that regardless of the territory in which the regulatory agencies are located, there is considerable convergence among Brazilian expectations and those of the other health authorities consulted. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-07-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1710 |
url |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1710 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1710/1206 https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1710/1277 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/3.0/deed.pt_BR info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/3.0/deed.pt_BR |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Instituto Nacional de Controle de Qualidade em Saúde |
publisher.none.fl_str_mv |
Instituto Nacional de Controle de Qualidade em Saúde |
dc.source.none.fl_str_mv |
Health Surveillance under Debate: Society, Science & Technology ; Vol. 8 No. 3 (2020): August; 44-51 Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 8 Núm. 3 (2020): Agosto; 44-51 Vigil Sanit Debate, Rio de Janeiro; v. 8 n. 3 (2020): Agosto; 44-51 2317-269X reponame:Vigilância Sanitária em Debate instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Vigilância Sanitária em Debate |
collection |
Vigilância Sanitária em Debate |
repository.name.fl_str_mv |
Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
incqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br |
_version_ |
1797042046048927744 |